[go: up one dir, main page]

DE69942365D1 - Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben - Google Patents

Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben

Info

Publication number
DE69942365D1
DE69942365D1 DE69942365T DE69942365T DE69942365D1 DE 69942365 D1 DE69942365 D1 DE 69942365D1 DE 69942365 T DE69942365 T DE 69942365T DE 69942365 T DE69942365 T DE 69942365T DE 69942365 D1 DE69942365 D1 DE 69942365D1
Authority
DE
Germany
Prior art keywords
binding domain
fusion polypeptide
collagen binding
nucleic acid
acid sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69942365T
Other languages
English (en)
Inventor
Frederick L Hall
Erlina M Gordon
Vaughn A Starnes
W French Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Application granted granted Critical
Publication of DE69942365D1 publication Critical patent/DE69942365D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
DE69942365T 1998-07-31 1999-07-30 Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben Expired - Lifetime DE69942365D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/127,134 US6387663B1 (en) 1998-07-31 1998-07-31 Targeting pharmaceutical agents to injured tissues
PCT/US1999/017297 WO2000006195A1 (en) 1998-07-31 1999-07-30 Targeting pharmaceutical agents to injured tissues

Publications (1)

Publication Number Publication Date
DE69942365D1 true DE69942365D1 (de) 2010-06-24

Family

ID=22428477

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69942365T Expired - Lifetime DE69942365D1 (de) 1998-07-31 1999-07-30 Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben

Country Status (11)

Country Link
US (2) US6387663B1 (de)
EP (1) EP1100535B1 (de)
JP (1) JP4564657B2 (de)
AT (1) ATE467425T1 (de)
AU (1) AU758483B2 (de)
CA (1) CA2337979A1 (de)
DE (1) DE69942365D1 (de)
ES (1) ES2346275T3 (de)
IL (3) IL141141A0 (de)
NZ (1) NZ509804A (de)
WO (1) WO2000006195A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2378925C (en) * 1999-07-21 2010-04-06 University Of Southern California Matrix-targeted fusion polypeptides for tissue regeneration and wound healing
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US8460367B2 (en) 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
JP5859179B2 (ja) * 2000-03-15 2016-02-10 オーバスネイチ メディカル、インコーポレイテッド 内皮細胞接着を促進するコーティング
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US7547674B2 (en) * 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2002014505A1 (fr) * 2000-08-15 2002-02-21 Terumo Kabushiki Kaisha Polypeptide hybride de fixation du collagene
WO2002030443A2 (en) * 2000-10-11 2002-04-18 The Wistar Institute Regulation of human skin healing
ES2186501B1 (es) * 2000-11-23 2006-05-16 Universidad De Malaga Factor de crecimiento fibroblastico basico con un dominio de union especifico a colegeno.
WO2003018752A2 (en) 2001-08-23 2003-03-06 The Wistar Institute Of Anatomy And Biology An organotypic intestinal culture and methods of use thereof
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7060684B1 (en) 2002-12-16 2006-06-13 Quijano Rodolfo C Device for treating diabetes and methods thereof
US8192348B2 (en) * 2003-07-01 2012-06-05 Regents Of The University Of Minnesota Engineered blood vessels
US20090035257A1 (en) * 2005-08-25 2009-02-05 Repair Technologies, Inc. Devices, compositions and methods for the protection and repair of cells and tissues
US8802396B2 (en) 2005-12-26 2014-08-12 Yantai Zhenghai Bio-Technology Co., Ltd. Activated collagen scaffold materials and their special fused active restoration factors
CN105327393A (zh) 2006-06-22 2016-02-17 南佛罗里达大学 胶原支架、具有其的医用植入物以及使用方法
DE102007010306A1 (de) * 2007-02-22 2008-08-28 Eberhard-Karls-Universität Tübingen Universitätsklinikum Bispezifisches Fusionsprotein mit therapeutischem und diagnostischem Potenzial
DK3091075T3 (en) 2007-04-09 2018-07-16 Univ Arkansas FUSION PROTEINS OF COLLAGEN-BINDING DOMAIN AND PARATHYRO OIDA HORMON
JP5260976B2 (ja) * 2008-02-08 2013-08-14 東ソー株式会社 血液凝固第ｖｉｉｉ因子ｃ２ドメインタンパク質の製造方法
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CN101671396B (zh) * 2008-09-11 2012-07-18 烟台正海生物技术有限公司 与胶原蛋白特异结合的血管内皮生长因子及其应用
BR112012029611A2 (pt) 2010-05-21 2017-07-25 Merrimack Pharmaceuticals Inc proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico
CN104634971A (zh) * 2010-07-19 2015-05-20 霍夫曼-拉罗奇有限公司 鉴定响应抗癌疗法的可能性升高的患者的方法
US9173919B2 (en) 2011-02-16 2015-11-03 Purdue Research Foundation Collagen-targeted nanoparticles
EP3391899B1 (de) 2011-12-14 2020-07-15 The Board of Trustees of the University of Arkansas Abgabe therapeutischer wirkstoffe über ein kollagenbindungsprotein
US9526765B2 (en) 2012-02-09 2016-12-27 The Kitasato Institute Delivery of therapeutic agents by a collagen binding protein
US10420820B2 (en) 2014-09-29 2019-09-24 Counterpoint Biomedia LLC Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polypeptides
CN106188306B (zh) * 2015-05-04 2020-07-24 北京同建再生医学技术有限公司 治疗性重组抗体、其编码基因及应用
ES2863278T3 (es) 2015-10-02 2021-10-11 Silver Creek Pharmaceuticals Inc Proteínas terapéuticas biespecíficas para la reparación de tejidos
WO2017218355A1 (en) 2016-06-15 2017-12-21 Counterpoint Biomedica Llc Polypeptide targeting aptamers for characterization, capture, and clinical management of circulating tumor cells
JP2020501510A (ja) * 2016-09-20 2020-01-23 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 目の表面で使用するためのアンカードメインを含む繋留タンパク質に基づく薬物
US10913779B2 (en) 2017-01-25 2021-02-09 Counterpoint Biomedica Llc Exposed collagen-targeted fusion cytokine for immune modulation in invasive cancers and lesions of infections
US11624060B2 (en) 2017-02-10 2023-04-11 The Board Of Trustees Of The University Of Arkansas Collagen-binding agent compositions and methods of using the same
CN109125710A (zh) * 2017-06-15 2019-01-04 中国科学院遗传与发育生物学研究所 胶原靶向血管内皮生长因子在陈旧性心肌梗死治疗中的应用
AU2019231307A1 (en) 2018-03-09 2020-10-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Delivering biological drugs to tissues
JP7630426B2 (ja) 2018-10-23 2025-02-17 ドラゴンフライ セラピューティクス， インコーポレイテッド ヘテロ二量体ｆｃ融合タンパク質
CA3148621A1 (en) * 2019-07-25 2021-01-28 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
CN113121700B (zh) * 2019-12-30 2023-06-13 独步吾奇生物医疗科技(江苏)有限公司 与胶原特异结合的重组蛋白、其编码基因及应用
EP4138778A1 (de) 2020-04-22 2023-03-01 Dragonfly Therapeutics, Inc. Formulierung, dosierungsplan und herstellungsverfahren für heterodimere fc-kondensierte proteine
WO2022256568A1 (en) * 2021-06-02 2022-12-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for localization of growth factors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE120206T1 (de) * 1986-05-30 1995-04-15 Scripps Clinic Res Peptide, die die bindung des von-willebrand- faktors inhibieren.
US5800811A (en) * 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
EP2008664B1 (de) * 1997-04-10 2012-08-29 University Of Southern California Modifizierte Proteine zur Bindung extrazellulärer Matrixkomponenten
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions

Also Published As

Publication number Publication date
EP1100535B1 (de) 2010-05-12
EP1100535A4 (de) 2004-12-29
WO2000006195A1 (en) 2000-02-10
AU758483B2 (en) 2003-03-20
NZ509804A (en) 2003-07-25
US20020164719A1 (en) 2002-11-07
IL141141A0 (en) 2002-02-10
US6955898B2 (en) 2005-10-18
ATE467425T1 (de) 2010-05-15
CA2337979A1 (en) 2000-02-10
JP4564657B2 (ja) 2010-10-20
IL141141A (en) 2008-07-08
ES2346275T3 (es) 2010-10-13
AU5328699A (en) 2000-02-21
US6387663B1 (en) 2002-05-14
JP2002521044A (ja) 2002-07-16
EP1100535A1 (de) 2001-05-23
IL190793A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
DE69942365D1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
ES2107041T3 (es) Variantes de activador de plasminogeno tisular obtenidos por glicosilacion, que presentan propiedades terapeuticas.
DE69834267D1 (de) Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
ATE393831T1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
BR0109494A (pt) Produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
PT923570E (pt) Amidas de acidos piridil-alcenoicos e piridil-alcinicos como agentes citostaticos e imunossupressivos
ATE342067T1 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
EP1117672A4 (de) Antisense-modulation der survivin-expression
DE69434926D1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
ATE352639T1 (de) Antisense modulation der expression von integrin alpha 4
EA200000378A1 (ru) Усеченные по амино-концу мср-2 как антагонисты хемокинов
AR023482A1 (es) Acidos nucleicos que codifican polipeptidos quimericos cd40/cd4ol, metodos para su produccion y usos de los mismos
DE69835680D1 (de) Therapeutische verwendung von smr1 protein und seinen aktiven derivaten
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
DE60025830D1 (de) Fusions-polypeptide zur gewebegeneration und wundheilung zur gezielten matrixanwendung
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
PT994884E (pt) Sais de acido difosfonico para o tratamento da osteoporose
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
ATE349521T1 (de) Mit cd40 und traf interagierende proteine
ATE325812T1 (de) Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors
DK0811068T3 (da) Humane DNase I varianter
ATE362531T1 (de) Interne ribosom eintrittstelle (ires), vektor der diesen enthaltet und dessen therapeutische verwendung
MX9803801A (es) Colagena de tipo ix y quimeras.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition